UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 60

Sortiert nach

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Blood, 2015-12, Vol.126 (26), p.2798-2804

2015

Volltextzugriff (PDF)

Determinants of Tax Ethics in Society: Statistical and Logistic Regression Approach

Mathematics (Basel), 2023-05, Vol.11 (10), p.2341

2023

Volltextzugriff (PDF)

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Clinical cancer research, 2005-08, Vol.11 (16), p.5984-5992

2005

Volltextzugriff (PDF)

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Oncotarget, 2017-05, Vol.8 (19), p.31478-31493

2017

Volltextzugriff (PDF)

Proteasome inhibitors in mantle cell lymphoma

Best practice & research. Clinical haematology, 2012-06, Vol.25 (2), p.133-141

2012

Volltextzugriff (PDF)

Remission of rheumatoid arthritis on brentuximab vedotin

Rheumatology (Oxford, England), 2014-12, Vol.53 (12), p.2314-2315

2014

Volltextzugriff (PDF)

Amyloidosis: A rare disease with varied manifestations

Current problems in cancer, 2016-09, Vol.40 (5), p.181-182

Holkova, Beata

2016

Volltextzugriff (PDF)

Phase Ib study of brentuximab vedotin (BV) with low-dose total skin electron beam (LD-TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e20037-e20037

2020

Volltextzugriff (PDF)

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

The New England journal of medicine, 2018-01, Vol.378 (4), p.331-344

2018

Volltextzugriff (PDF)

Statistical Learning as a Tool for Optimizing the Level of Excise Tax of Mineral Oils in Slovakia

Procedia engineering, 2017, Vol.192, p.318-323

2017

Volltextzugriff (PDF)

Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy

Journal of clinical oncology, 2001-09, Vol.19 (18), p.3848-3851

2001

Volltextzugriff (PDF)

Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study

JOURNAL OF CLINICAL ONCOLOGY, 2022, Vol.40 (16_suppl), p.8019-8019

2022

Volltextzugriff (PDF)

Bortezomib for the treatment of non-Hodgkin's lymphoma

Expert opinion on pharmacotherapy, 2014-11, Vol.15 (16), p.2443-2459

2014

Volltextzugriff (PDF)

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

BLOOD, 2021-11, Vol.138 (Supplement 1), p.897-897

2021

Volltextzugriff (PDF)

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS8552-TPS8552

2020

Volltextzugriff (PDF)

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Oncotarget, 2019-09, Vol.10 (51), p.5383-5384

2019

Volltextzugriff (PDF)

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Blood, 2019-11, Vol.134 (Supplement_1), p.1857-1857

2019

Volltextzugriff (PDF)

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

BLOOD, 2020-11, Vol.136 (Supplement 1), p.1-2

2020

Volltextzugriff (PDF)

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Future oncology (London, England), 2021-06, Vol.17 (16), p.1987-2003

2021

Volltextzugriff (PDF)

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Leukemia & lymphoma, 2021-04, Vol.62 (5), p.1187-1194

2021

Volltextzugriff (PDF)

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

Leukemia & lymphoma, 2018-11, Vol.59 (11), p.2588-2594

2018

Volltextzugriff (PDF)

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Clinical cancer research, 2016-03, Vol.22 (5), p.1067-1075

2016

Volltextzugriff (PDF)

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

Expert review of hematology, 2011-10, Vol.4 (5), p.483-486

2011

Volltextzugriff (PDF)

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2018-09, Vol.18 (9), p.569-575.e1

2018

Volltextzugriff (PDF)

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Leukemia & lymphoma, 2017-06, Vol.58 (6), p.1349-1357

2017

Volltextzugriff (PDF)

1 – 25 von 60

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(59)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Humans
(24)
Life Sciences & Biomedicine
(23)
Oncology
(17)
Male
(16)
Female
(15)
Adult
(14)
Middle Aged
(14)
Aged
(12)
Hematology
(10)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(9)
Treatment Outcome
(9)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(7)
Bortezomib
(7)
Aged, 80 And Over
(6)
Lymphoma
(6)
Disease-Free Survival
(5)
Antineoplastic Agents
(4)
Biological And Medical Sciences
(4)
Carfilzomib
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Determinants of Tax Ethics in Society: Statistical and Logistic Regression Approach

Immunomodulatory Drug CC-5013 or CC-4047 and Rituximab Enhance Antitumor Activity in a Severe Combined Immunodeficient Mouse Lymphoma Model

Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin's lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Proteasome inhibitors in mantle cell lymphoma

Remission of rheumatoid arthritis on brentuximab vedotin

Amyloidosis: A rare disease with varied manifestations

Phase Ib study of brentuximab vedotin (BV) with low-dose total skin electron beam (LD-TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Statistical Learning as a Tool for Optimizing the Level of Excise Tax of Mineral Oils in Slovakia

Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy

Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study

Bortezomib for the treatment of non-Hodgkin's lymphoma

DREAMM-5 Study: Investigating the Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with relapsed/refractory multiple myeloma (RRMM)

Correction: Synergistic interactions between PLK1 and HDAC inhibitors in non-Hodgkin’s lymphoma cells occur in vitro and in vivo and proceed through multiple mechanisms

Dreamm-5: Platform Trial Evaluating Belantamab Mafodotin (a BCMA-directed Immuno-conjugate) in Combination with Novel Agents in Relapsed or Refractory Multiple Myeloma (RRMM)

Dreamm-5 Platform Trial: Belantamab Mafodotin (Belamaf) in Combination with Four Different Novel Agents in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

Phase 1 study of belinostat (PXD-101) and bortezomib (Velcade, PS-341) in patients with relapsed or refractory acute leukemia and myelodysplastic syndrome

Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

Combining proteasome with cell cycle inhibitors: a dual attack potentially applicable to multiple hematopoietic malignancies

A Phase II Trial of Bortezomib and Vorinostat in Mantle Cell Lymphoma and Diffuse Large B-cell Lymphoma

A phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma

Suchergebnisse filtern